Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jong-Mu Sun

Showing results (271-280 of 303) with videos related to

Pageof 31
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 6, 2026
JIN-A02, a Mutant-Selective Fourth-Generation EGFR inhibitor, Overcomes C797S-Mediated Resistance and Demonstrates Intracranial Activity in NSCLCEun Ji Lee, Ji Ae Ko, Min-Je Kim, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 12, 2023
Longitudinal Monitoring of Circulating Tumor DNA From Plasma in Patients With Curative Resected Stages I to IIIA EGFR-Mutant Non-Small Cell Lung CancerHyun-Ae Jung, Bo Mi Ku, Yeon Jeong Kim, et al.
Oncotarget|May 7, 2017
Tissue recommendations for precision cancer therapy using next generation sequencing: a comprehensive single cancer center's experiencesMinho Cho, Soomin Ahn, Mineui Hong, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|June 5, 2015
Phase II trial of epidermal growth factor ointment for patients with Erlotinib-related skin effectsIn Gyu Hwang, Jung Hun Kang, Sung Yong Oh, et al.
Journal for Immunotherapy of Cancer|October 20, 2020
Clinical advantage of targeted sequencing for unbiased tumor mutational burden estimation in samples with low tumor purityTae Hee Hong, Hongui Cha, Joon Ho Shim, et al.
The Lancet. Oncology|December 24, 2011
Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 studyJeeyun Lee, Se Hoon Park, Heung-Moon Chang, et al.
Journal for Immunotherapy of Cancer|October 31, 2025
Artificial intelligence-powered spatial analysis of tumor microenvironment in patients with non-small cell lung cancer with acquired resistance to EGFR tyrosine kinase inhibitorYeong Hak Bang, Geun-Ho Park, Jin Woo Oh, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 19, 2025
Perioperative Pembrolizumab for Locally Advanced Thymic Epithelial Tumors: A Single-Arm, Phase 2 TrialYeong Hak Bang, Jae Myoung Noh, Boram Lee, et al.
Ebiomedicine|March 16, 2024
Comprehensive analysis of transcription factor-based molecular subtypes and their correlation to clinical outcomes in small-cell lung cancerSehhoon Park, Tae Hee Hong, Soohyun Hwang, et al.
World Journal of Gastroenterology|April 21, 2015
Weekly docetaxel and gemcitabine in previously treated metastatic esophageal squamous cell carcinomaMin-Young Lee, Ki Sun Jung, Hae Su Kim, et al.
Pageof 31

Showing results (271-280 of 303) with videos related to

Sort By:
Pageof 31
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 6, 2026
JIN-A02, a Mutant-Selective Fourth-Generation EGFR inhibitor, Overcomes C797S-Mediated Resistance and Demonstrates Intracranial Activity in NSCLCEun Ji Lee, Ji Ae Ko, Min-Je Kim, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 12, 2023
Longitudinal Monitoring of Circulating Tumor DNA From Plasma in Patients With Curative Resected Stages I to IIIA EGFR-Mutant Non-Small Cell Lung CancerHyun-Ae Jung, Bo Mi Ku, Yeon Jeong Kim, et al.
Oncotarget|May 7, 2017
Tissue recommendations for precision cancer therapy using next generation sequencing: a comprehensive single cancer center's experiencesMinho Cho, Soomin Ahn, Mineui Hong, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|June 5, 2015
Phase II trial of epidermal growth factor ointment for patients with Erlotinib-related skin effectsIn Gyu Hwang, Jung Hun Kang, Sung Yong Oh, et al.
Journal for Immunotherapy of Cancer|October 20, 2020
Clinical advantage of targeted sequencing for unbiased tumor mutational burden estimation in samples with low tumor purityTae Hee Hong, Hongui Cha, Joon Ho Shim, et al.
The Lancet. Oncology|December 24, 2011
Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 studyJeeyun Lee, Se Hoon Park, Heung-Moon Chang, et al.
Journal for Immunotherapy of Cancer|October 31, 2025
Artificial intelligence-powered spatial analysis of tumor microenvironment in patients with non-small cell lung cancer with acquired resistance to EGFR tyrosine kinase inhibitorYeong Hak Bang, Geun-Ho Park, Jin Woo Oh, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 19, 2025
Perioperative Pembrolizumab for Locally Advanced Thymic Epithelial Tumors: A Single-Arm, Phase 2 TrialYeong Hak Bang, Jae Myoung Noh, Boram Lee, et al.
Ebiomedicine|March 16, 2024
Comprehensive analysis of transcription factor-based molecular subtypes and their correlation to clinical outcomes in small-cell lung cancerSehhoon Park, Tae Hee Hong, Soohyun Hwang, et al.
World Journal of Gastroenterology|April 21, 2015
Weekly docetaxel and gemcitabine in previously treated metastatic esophageal squamous cell carcinomaMin-Young Lee, Ki Sun Jung, Hae Su Kim, et al.
Pageof 31